Title: Cancer as a novel Risk Factor for Major Adverse Cardiovascular Events in Secondary Prevention

1 2 3 4 5 6 7 Authors: Renzo Melchiori MD¹, Sara Diaz Saravia MD², Pablo Rubio MD¹, Lucas Szlaien MD¹, Romina Mouriño¹ MD, Martin O'Flaherty³ MD, MSc, PhD, Miguel Rizzo MD PhD⁴, Alejandro Hita MD PhD¹

- Affiliations:
- ¹Department of Cardiology and Echocardiography, Hospital Universitario Austral, Austral University, Buenos
- 8 Aires, Argentina
- 9 ²Department of Medicine, Icahn School of Medicine at Mount Sinai
- 10 ³Department of Public Health, Policy and Systems, University of Liverpool, United Kingdom
- 11 ⁴Department of Hematology and Oncology, Hospital Universitario Austral, Austral University, Buenos Aires, 12 Argentina
- 13
- 14 Short Title: Cancer as a Risk Factor in Secondary Prevention
- 15

16 **Corresponding Author:**

- 17 Renzo Melchiori MD¹
- 18 rmelchio@cas.austral.edu.ar
- 19 Department of Cardiology and Echocardiography, Hospital Universitario Austral, Austral University, Buenos
- 20 Aires, Argentina
- 21 +54 (11)-31073969
- 22
- 23 Word Count: 4834

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

24 Abstract

Introduction: The inflammatory mechanisms of cancer can be associated with atherosclerosis development and progression. Although there is an incidence rate of cardiovascular events in secondary prevention following a first acute coronary syndrome (ACS).

Methods: A retrospective study cohort study including patients who underwent a PCI for first Acute Coronary Syndrome (ACS), and without prior history of Major Cardiovascular Events (MACE) from 2008 to 2022 was analyzed. Included patients were grouped according to the absence or presence of cancer: G1 non-oncologic, and G2 oncologic (either prior or actual history). We compared the incidence rate ratio of MACE within 3 years after STEMI between groups Time-to-event analysis was conducted through proportional Cox regression analysis, estimating hazard ratio, and corresponding 95% confidence intervals (95% CI)

35

28

Results: Out of 937 patients who underwent a PCI, 787 patients were included of which 88.7% (n=698) presented without cancer. Over a median follow-up time of 45 months [IQR= 14-72], the incidence rate of MACE was 4.4 cases per 1000 patients/months of follow-up (n=173 MACE events). When comparing both groups, the incidence rate ratio of MACE was 1.9 (95% CI 1.24-2.99), significantly increased in the cancer group (P=0.0032) without showing differences in median follow-up times. Cancer was an independent predictor of MACE HR 1.84 (95% CI 1.19-2.85; P=0.006), adjusted for hypertension, dyslipidemia, diabetes, smoking history, sedentary lifestyle, obesity, age, male gender, and family history of cardiovascular disease.

43

44 **Conclusions:** Patients with cancer represent a novel independent risk factor for MACE, even following 45 secondary preventive therapies. These results highlight future endpoints for cardiovascular prevention and 46 further public health interventions on this population.

47 INTRODUCTION

48 Cancer is the second cause of death worldwide, only surpassed by cardiovascular diseases (1). In recent 49 decades, cancer mortality rates have decreased, with a consequent increase in overall survival (2). For those 50 patients who survive cancer, oncological treatments and cardiovascular and cerebrovascular diseases become 51 the main causes of mortality (3, 4). In 2022, there were approximately 4.2 million cases of cancer in the region 52 of the Americas, and this number is projected to increase up to 6.7 million in 2045 according to the Pan-53 American Health Organization. This growing number calls for a better understanding of the relationship of 54 cancer and cardiovascular disease in the long term.

55

56 Multiple studies have emphasized the relationship between the pathophysiological mechanisms of cancer and 57 cardiovascular disease (5-6). There is emerging evidence on the role of oncological disease as a precipitator of 58 chronic inflammation and long-term endothelial damage (7-11). Although there are multiple registry 59 publications in relation to the increase in cardiovascular events in the cancer population (3, 5, 17-21), the 60 evidence for secondary prevention is scarce.

61

62 However, less is known in terms of the excess risk of cancer on Major Adverse Cardiovascular Events (MACE) in 63 the context of secondary prevention. If this association exists, its role in modifying management and 64 prognostic strategies will need to be defined, implying a significant impact in public health and cardiovascular 65 prevention. Therefore, we sought to determine the independent association of oncological disease and its 66 effect on the incidence of MACE compared to patients without cancer in the secondary prevention setting.

67 68 **METHODS**

69 Setting and Study Design

A retrospective cohort study was conducted including adult patients (>17 years of age) who were admitted to the Cardiac Care Unit at the Austral University Hospital with Acute Coronary Syndrome (ACS) from January 1st, 2009, to March 31st, 2023. This registry was formed through the review of Electronic Medical Records of patients presenting with ACS during that period, and subjects were selected according to the eligibility criteria defined (see section "Eligibility Criteria"). Institutional Ethical Approval was granted by the Ethics Board and written informed consent was obtained from the patients before their admission to the institution (Institutional Evaluation Committee of the Universidad Austral, CIE No. P21-022).

78 Eligibility Criteria

Patients eligible for this study included those who underwent Left Heart Catheterization (LHC) as part of the
 therapeutic diagnostic strategy during their first hospitalization due to ACS. Patients with prior history of
 Myocardial Infarction (MI), or Cerebrovascular disease (CVA), or either percutaneous Coronary Intervention
 (PCI) or Coronary Artery Bypass Graft Surgery (CABG) were excluded.

83

84 Exposure variable of interest

85 The exposure group was defined as any active oncological history (under treatment) or referred, regardless of 86 its duration, prior to entry into the cohort, irrespective of the type of treatment received. The cancer history 87 necessary for our study was obtained from the patient's electronic medical records. It was characterized by the 88 type of neoplasm, defining hematologic neoplasia as leukemia, lymphomas, myeloproliferative syndromes, 89 and multiple myeloma, and solid organ tumors as any tumor that is non-hematological, establishing cellular 90 type where possible. The years since diagnosis were determined as the time from cancer diagnosis to 91 admission to the coronary unit or cardiovascular study as part of the admission. Oncological stage was 92 established according to the TNM classification system.

93

94 Regarding cancer therapies, it was assessed whether patients were under active treatment or not. Active 95 chemotherapy was defined as having received chemotherapy or immunotherapy within 90 days prior to initial 96 hospital presentation. Specific treatment types were categorized into chemotherapy, immunotherapy, 97 hormone therapy, and radiotherapy. Radiation therapy history was defined as radiation treatment to any 98 organ, establishing the cumulative dose, if possible, as the oncological treatment may have been administered 99 at another institution. It was also determined whether anthracyclines were used in the oncological treatment. 100 The time since completion of treatment was established in years at the time of admission for acute coronary 101 syndrome (ACS). Skin cancer basal cell carcinoma or squamous cell carcinoma were excluded.

102 103

104 Other exposure variables of interest and co-interventions

105 The known risk factors were collected by the attending physician upon admission for the ACS in the electronic 106 medical records, including hypertension defined as systolic blood pressure greater than or equal to 140 mmHg 107 and/or diastolic blood pressure greater than or equal to 90 mmHg or the use of antihypertensive medications 108 at the time of hospitalization. Diabetes mellitus was defined as HbA1c levels greater than 6.5 mg/dL in the 109 laboratory and/or documented history in the medical record and/or use of insulin. Smoking history was 110 considered, including former and active smokers. Dyslipidemia was defined as values above normal for total 111 cholesterol, LDL cholesterol, and/or triglycerides, as well as the use of lipid-lowering medications. Obesity was 112 defined as a body mass index equal to or greater than 30. Sedentary lifestyle was defined as less than 2.5 113 hours of exercise per week, and family history included the presence of myocardial infarction or stroke in a 114 first-degree relative before the age of 55 for men or 65 for women.

115

116 The clinical variables and laboratory tests to assess adherence to secondary prevention goals were rate of 117 statins rate, dosing of statins (standardized to equivalent doses of atorvastatin), LDL value (mg/dl), use of dual 118 antiplatelet therapy (DAPT), duration of DAPT and use of Aspirin. These parameters were measured in both

- 119 oncology and non-oncology patients as part of their follow-up.
- 120

121 Primary outcome assessment, definition, and statistical analysis.

The primary endpoint was the incidence rate of new MACE over the follow-up period since hospital discharge after the primary ACS. MACE was defined as a composite of death by cardiovascular cause, non-fatal Myocardial Infarction (MI), non-fatal Cerebrovascular Accident (CVA), and repeat non-staged Percutaneous Coronary Intervention (PCI). Cardiovascular death was considered when the patient was admitted due to a MACE. This does not include patients admitted for non-cardiovascular events who subsequently developed STEMI or CVA during their hospitalization. The non-fatal myocardial infarction was considered using the current universal definition of myocardial infarction at the time of admission (14).

129

Stroke was defined as compatible clinical symptoms plus imaging findings of brain injury on computed tomography or magnetic resonance imaging (15). In our study, scheduled angioplasty was considered for all PCI procedures performed after one month from the primary event due to symptoms or ischemia on stress test.

The surveillance follow-up for MACE in each patient was conducted by the Primary Care Physician (PCP) or the Principal Cardiologist. Patients who were not followed up at our institution were contacted by phone by medical personnel who underwent a structured interview. (Table S5)

137

The secondary endpoint was the comparison of incidence rates of MACE in subpopulations of patients without prior radiotherapy in any body region, and in patients without active chemotherapy at the time of ACS. The objectives of secondary prevention were also derived from the Electronic Medical Record (EMR) data and were aligned with the current guidelines of the American College of Cardiology (ACC) and the European Society of Cardiology (ESC), conducted by the Primary Care Physician (PCP) or the Principal Cardiologist. These parameters were measured in both oncological and non-oncological patients as part of their follow-up.

145 para 144

We estimated a sample power for time-to-event analysis, considering an alpha and beta error of 0.05 and 0.2, respectively. Following the Friedman method, a total number of 167 MACE over the follow-up were necessary to obtain a power of 80%. Categorical variables are reported as a frequency and percentage and subgroups were compared using Chi-square or Fisher exact test, as appropriate. Continuous variables are reported as

149 mean and standard deviation (±SD) or as median (IQR), and were compared using the t test or Wilcoxon, for

150 normal or non-parametric distribution, respectively. To determine whether cancer acted as an independent

151 predictor of MACE, adjusted for traditional cardiovascular risk factors, a Cox regression model was conducted.

152 Hazard ratios and its corresponding 95%CI were estimated. Performance of the final model was evaluated

153 through calibration (observed vs expected outcomes) and discrimination with Harrell's c-statistics index.

154 Kaplan-Meier survival curves were computed and compared using the log-rank test. The same analysis was

155 performed with the secondary objective subpopulations. All statistical analyses were performed with Stata®

- 156 17.0BE.
- 157
- 158 **RESULTS**

An initial screening process detected 937 patients who had presented to our hospital for ACS and had undergone a LHC as part of their work-up. Of those patients, we excluded 35 patients who had undergone CABG, 31 CVA, prior myocardial infarction 23, death 21, and 40 patients were lost to follow-up. These patients who had been lost to follow-up were looked-up on national registries to ensure they were not deceased. A total of 787 patients who completed follow-up were included, 698 (88.7%) without cancer (G1) and 89 (11.3%) with a history of cancer or active cancer (G2). The median follow-up time for the entire cohort was 48 months (IQR=15-72), being 48 months (IQR=15-84) for G1 and 36 months (IQR=11-48) (0.03).

166

Patients with cancer were significantly older (67 years/±10 vs 60.2 years ±11, p 0.0001) and had a higher prevalence of insulin-dependent diabetes mellitus (10% vs 4%, p=0.01). The rest of the baseline characteristics can be seen in Table 1. The therapeutic strategies and general therapeutic objectives for the management of

ACS were adjusted to the guidelines available at that time (Table S1). There were no significant differences in LHC findings between the two groups, as seen on Table 1.

172

173 Figure 1. Flow chart of patient selection



174 175 176

Table 1. Baseline Characteristics of both subpopulations at the time of ACS presentation

| Variables | Total (N=787) | G1 (N=698) | G2 (N=89) | P Value |
|--|---------------|----------------|--------------|---------|
| Age (years) | 61 (SD ± 11) | 60.2 (SD ± 11) | 67 (SD ± 10) | 0.0001 |
| Male Sex | 645 (82%) | 572 (81.9%) | 73 (82%) | 0.98 |
| Hypertension | 496 (63%) | 441 (63.2%) | 55 (61.8%) | 0.78 |
| No DM | 625 (79.4) | 563 (80.5%) | 63 (71%) | 0.03 |
| NIDDM | 125 (17.5%) | 108 (15.5%) | 17 (19%) | 0.38 |
| IDDM | 37 (4.7%) | 28 (4%) | 9 (10%) | 0.56 |
| History of Smoking | 480 (61%) | 430 (62%) | 50 (56%) | 0.32 |
| Dyslipidemia | 494 (62.7%) | 442 (63.2%) | 52 (58.4%) | 0.33 |
| Hyperuricemia | 19 (2.41%) | 16 (2.29%) | 3 (3.7%) | 0.53 |
| Obesity | 290 (36.9%) | 267 (38.3%) | 23 (25.8%) | 0.022 |
| Family History of Cardiovascular Disease | 137 (17.4%) | 130 (18.6%) | 7 (7.9%) | 0.012 |
| Sedentarism | 441 (56%) | 405 (58%) | 36 (40.4%) | 0.002 |
| Length of Stay (days) | 3 (IQR 2-5) | 3 (IQR 2-6) | 4 (IQR 3-5) | 0.1 |
| Mean LVEF at time of Discharge (%) | 54 (±10.5) | 54 (±10) | 53 (±11) | 0.44 |
| Number of Affected vessels | | | | |
| 0 | 72 (9.15%) | 61 (8.74%) | 11 (12.3%) | 0.26 |
| 1 | 338 (42.9%) | 306 (43.8%) | 32 (35.9%) | 0.15 |
| 2 | 277 (35.2%) | 244 (34.9%) | 33 (37.1%) | 0.69 |
| 3 | 100 (12.7%) | 87 (12.5%) | 13 (14.6%) | 0.59 |
| Left Main | 20 (2.54%) | 18 (2.58%) | 2 (2.25%) | 0.851 |

| Left Anterior Descending | 475 (60.4%) | 421 (60.3%) | 54 (60.7%) | 0.94 |
|---------------------------|-------------|-------------|------------|-------|
| Left Circumflex | 314 (39.9%) | 276 (39.5%) | 38 (42.7%) | 0.56 |
| Right Coronary | 363 (46.1%) | 315 (45.1%) | 48 (53.9%) | 0.11 |
| Number of Treated Lesions | | | | |
| 1 | 405 (51.4%) | 368 (53.5%) | 37 (41.6%) | 0.05 |
| 2 | 239 (30.4%) | 209 (30.3%) | 30 (33.7%) | 0.58 |
| 3 | 70 (8.89%) | 59 (8.6%) | 11 (12.3%) | 0.224 |
| BARC Score | | | | |
| 0 | 579 (73.6%) | 476 (68.2%) | 67 (75.3%) | 0.74 |
| 1 | 188 (23.9%) | 202 (28.9%) | 20 (22.5%) | 0.69 |
| 2 | 16 (2.03%) | 15 (2.15%) | 1 (1.12%) | 0.51 |
| 3 | 4 (0.51%) | 3 (0.43%) | 1 (1.12%) | 0.32 |

G1= Non-Oncologic Group, G2= Oncologic Group, DM= Diabetes Mellitus, NIDDM= Non-Insulin Dependent
 Diabetes Mellitus, IDDM= Insulin-Dependent Diabetes Mellitus.

The median time from cancer diagnosis to cohort entry was 24 months for G2. The cell line and staging characteristics of the oncology population can be seen in Table S1-S2. The objectives and management of secondary prevention were aligned with the guidelines in effect at the time of MACE. There were no statistically significant differences between LDL values, statin adherence, statin dose, DAPT and aspirin use between the two groups at the time of MACE (Table S4).

184 185 *Incidence*

A total of 173 (21.9%) MACE were identified in the follow-up period in both groups combined. The cumulative incidence of MACE for G1 was 21.06% (147/698) and for G2 was 29.3% (26/89). G2 presented a significantly higher incidence density of MACE when compared to G1 [8 MACE/1000 patients/month (95% CI 5.5-11.8) vs 4 MACE/1000 patients/month (95% CI 3. 4-4.8), p=0.0032]. The rate of cardiovascular death during the follow-up period was 4.5% for G2 and 0.14% for G1 (P=0.001). Other findings on the MACE events during the follow-up period can be found on Table 2. The non-cardiovascular mortality of the entire cohort during the follow-up period was 1.01%. In G2, non-cardiovascular death was higher than in G1 [5 (5.62%) vs 3 (0.43%), p = 0.001].

193

| 194 Table 2. Incidence of Major Adverse Cardiovascular Eve | nts |
|--|-----|
|--|-----|

| - | | | | |
|--------------------------------|---------------|--------------|------------|---------|
| MACE | Total (N=787) | G1 (N=698) | G2 (N=89) | P Value |
| Total MACE | 173 (21.9%) | 147 (21.06%) | 26 (29.2%) | 0.0016 |
| Cardiovascular Death | 5 (0.64%) | 1 (0.14%) | 4 (4.5%) | 0.001 |
| Nonfatal Myocardial Infarction | 101 (12.8%) | 90 (12.9%) | 11 (12.6%) | 0.13 |
| Nonfatal CVA | 4 (0.51%) | 2 (0.29%) | 2 (2.25%) | 0.0099 |
| Repeat PCI | 63 (8%) | 54 (7.7%) | 9 (10.5%) | 0.056 |

¹⁹⁵

198 The Kaplan Meier curve showed a statistically significant difference in time-to-MACE between the two groups, 199 with p=0.0015 (Figure 2) and a LR Chi 32.7.

200

201 Figure 2. Kaplan Meier Curve for Time-to-MACE.

¹⁹⁶ **P-value for incidence rate ratio*

¹⁹⁷





203 Multivariate Cox hazard analysis showed that cancer was an independent predictor of MACE (HR 1.84, [95% CI 204 1.19-2.85] p=0.006, Harrell's C p=0.63), adjusted for hypertension, dyslipidemia, diabetes, history smoking, 205 sedentary lifestyle, obesity, age, sex, and family history of cardiovascular disease.

206 207

Table 3. Multivariate Analysis for MACE

| Predictors for MACE | Hazard Ratio | 95% Confidence Interval | P Value |
|---------------------|--------------|-------------------------|---------|
| History of Cancer | 1.84 | 1.2-2.84 | 0.006 |
| Smoking history | 1.21 | 0.86-1.69 | 0.25 |
| Diabetes Mellitus | 1.29 | 0.90-1.86 | 0.16 |
| Age | 1.01 | 099-1.02 | 0.23 |
| Male Sex | 1.36 | 0.87-2.12 | 0.17 |
| Dyslipidemia | 1.1 | 0.79-1.54 | 0.56 |
| Obesity | 0.88 | 0.63-1.23 | 0.46 |
| Hypertension | 1.68 | 1.17-2.40 | 0.005 |
| Sedentarism | 1.13 | 0.80-1.60 | 0.46 |
| Family History | 0.75 | 0.48-1.18 | 0.22 |

208

209 Secondary Outcomes

A total of 65 patients with a history of cancer without prior radiotherapy were included in the subgroup analysis. The Cox analysis showed that Hazard Ratio (HR) of 1.92, (95% Cl 1.19- 3.08) p=0.007, adjusted for age, sex, and the classic risk factors for the oncology population. The Kaplan Meier curve comparing patients without prior radiotherapy again demonstrated a statistically significant difference between the two groups, with a p of 0.0021 (Figure 3).

The subgroup of patients without active chemotherapy consisted of 71 patients. The total number of MACE in this subgroup analysis was 165, with 147 events in G1 and 18 events in G2. The Kaplan-Meier curve comparing both subgroups showed p=0.043 (Figure 4). Cox Hazard analysis showed a non-significant difference between the incidence of MACE between the two groups, with an HR 1.61 (95% CI 0.97-2.68, p=0.066), adjusted for the risk factors mentioned above (Table S5)



136 96 62



101 167 381

305 204

608 603

- 231 232
- 232 733
- 233
- 234
- 235
- 236
- 237
- 238
- 239
- 240
- 241
- 242 243
- 244
- 245

246

247

Figure 4. Kaplan-Meier Curve for Time to MACE comparing oncologic patients Without Active Chemotherapy and non-oncologic patients.



250 251

252 **DISCUSSION**

The present work demonstrates that a history of cancer is an independent risk factor in the secondary prevention in our Latin American population, regardless of age at the time of ACS, gender, diabetes, high blood pressure, dyslipidemia, sedentary lifestyle, history of smoking and inherited family history. A first consideration to consider is that cancer patients have historically been poorly reflected in primary and secondary cardiovascular prevention studies due to systematic exclusion.

258

In our population, a history of cancer increased the risk of MACE by 84% during follow-up. The difference in rate of MACE in both groups during follow-up was mainly due to an increase in cardiovascular death and stroke; the other components of MACE were not statistically significant. Cardiovascular death could not be explained by differences in the therapeutic strategies carried out during hospitalization. The population with cancer received the same treatment as the general population, in accordance with current guidelines regarding the use of primary or rescue PCI as appropriate.

265

Left ventricular ejection fraction (LVEF) is an important factor for survival after a coronary event (22, 23), and at discharge, the LVEF was similar in both groups, indicating that an impaired LVEF at the time of discharge is unlikely to explain the association between cancer and MACE during follow-up in our cohort. Diabetes is also considered an independent risk factor for subsequent events as well (24, 25). In our cohort, diabetic cancer patients experienced 30% of events during follow-up, while diabetic patients without a history of cancer

experienced 27% of events, with no statistically significant differences.

Recently, Tabata et al. (20) and Wright et al (26), assessed the incidence of major cardiovascular events in patients with a history of cancer in a secondary prevention context without considering the management strategies or care quality of secondary prevention. Our study is consistent with these findings despite population differences, but we explicitly explored that the association was not due to lower attainment of cardiovascular secondary prevention targets.

In recent years, an emphasis has been made on the impact of radiotherapy as a risk factor for coronary atherosclerosis (27-29). In our population, the subgroup analysis excluding the history of radiotherapy showed the same results as the general population of the cohort. The analysis of patients without active oncological treatment presented a similar trend, with the survival curves being different from each other, demonstrating a strong epidemiological implication without the exposure variable being an independent risk factor because it did not reach statistical significance.

285

286 Previous studies have suggested that there might be some direct endothelial compromise with selected cancer 287 treatment in both pediatric and adult populations (9, 12-14). However, the rate of patients with active 288 chemotherapy treatment was 20% (18 out of 89 patients), and in the subgroup analysis the relationship 289 between cancer and worsened cardiovascular outcomes persisted. Therefore, in our results, this damage from 290 the oncologic treatment performed would not have an impact on generating distortion of the events, giving 291 greater value to the reported results. Patients with immunotherapies were underrepresented in our work, so 292 the results were not due to the atherogenic potentiation of these drugs. In summary, our results enhance an 293 association between oncological history and MACE beyond the cancer treatment strategy used. It would be 294 necessary to elucidate the individual impact of each therapy, type of cancer and latencies to give a specific 295 value to each situation and its future cardiovascular implication.

296

297 Currently, the inflammatory and multifactorial genesis of atheroma plaque is a well-established causal 298 mechanism. Among the possible pathophysiological mechanisms that would explain the findings, we believe 299 there would be a possible residual impact of endothelial inflammation linked to the oncological pathology and 300 the treatments received. Cancer, with its pro-inflammatory mechanisms and the deleterious effects of its 301 treatment, generates an increase in cytokines and pro-inflammatory factors that lead to an imbalance in 302 endothelial function, such as a decrease in Nitric Oxide, an increase in Endothelin-1, Interleukin-6 and Tumor 303 Growth Factors. (14, 30-33). Our study provides evidence that the association is likely real and not confounded 304 by other determinants of subsequent events in the cardiovascular secondary prevention setting. That suggests 305 a statistically significant and clinically relevant association between a history of cancer and the occurrence of 306 cardiovascular events in secondary prevention. Our results hence suggest the need to explore if patients with a 307 history of cancer should be considered for a stricter secondary prevention strategy, and further prospective 308 studies are needed to evaluate the true role of cancer in this phase. 309

310 Limitations

311 Our study was designed as a retrospective observational study and thus, data collection was limited to that 312 available at the time of the study, providing an inferior level of evidence compared to a prospective study. 313 Another limitation was that we adjusted for traditional cardiovascular risk factors such as hypertension, 314 smoking, diabetes, etc., but we did not adjust for frailty, low BMI, anemia, autoimmune disorders, among 315 other comorbidities that have been associated with worsening cardiovascular outcomes (34). Additionally, we 316 did not seek for the presence of clonal hematopoiesis of indeterminate potential (CHIP) in our cohort due to 317 insurance coverage limitations, despite being a condition associated with hematologic malignancy and 318 increased cardiovascular risk. Finally, the goals for secondary prevention for our cohort, such as optimal LDL 319 levels and statin doses, varied throughout our cohort given the rise of new guidelines with newer evidence.

320

321 CONCLUSION

322 In our population, the incidence rate ratio of major cardiovascular events was higher in cancer patients. 323 Oncological history behaved as an independent risk factor for major cardiovascular events, adjusted for classic 324 risk factors. These results highlight future endpoints for cardiovascular prevention and public health in this 325 population.

326

327 ACKNOWLEDGMENTS

RM was the designer and coordinator of this study SDS, LS, RM, and PR all contributed to data collection. RM and SDS did the data analysis. RM, SDS, MR, MOF, AL collaborated equally to the writing of this manuscript.

331 SOURCES OF FUNDING

332 None 333

330

336

340

334 **DISCLOSURES**

335 This manuscript received no financial support. The authors have no conflicts of interest.

337 SUPPLEMENTARY FILES

- 338 Supplementary Tables 1-5
- 339 Supplementary Methods 1

341 REFERENCES

- 342 1. Mattiuzzi C, Lippi G. Current Cancer Epidemiology. J Epidemiol Glob Health. 2019 Dec;9(4):217–22.
- 2. Torre LA, Siegel RL, Ward EM, Jemal A. Global Cancer Incidence and Mortality Rates and
- Trends—An Update. Cancer Epidemiology, Biomarkers & amp; Prevention. 2016 Jan 12;25(1):16–27.
- 345 3. Zaorsky NG, Churilla TM, Egleston BL, Fisher SG, Ridge JA, Horwitz EM, et al. Causes of death among cancer
 patients. Annals of Oncology. 2017 Feb 1;28(2):400–7.
- 247 A Affi ANA Good ANA AL Usessini AL Elesabusth AO Alerthfalt DV
- 347 4. Afifi AM, Saad AM, Al-Husseini MJ, Elmehrath AO, Northfelt DW, Sonbol MB. Causes of death after breast
 348 cancer diagnosis: A US population-based analysis. Cancer. 2020;126(7):1559-67.
- 349 5. Padegimas A, Clasen S, Ky B. Cardioprotective Strategies to Prevent Breast Cancer Therapy-Induced
 350 Cardiotoxicity. Trends Cardiovasc Med. 2020 Jan;30(1):22–8.
- 6. Zamorano JL, Lancellotti P, Rodriguez Munoz D, et al. 2016 ESC position paper on cancer treatments and
- 352 cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: the Task
- Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). Eur Heart J 2016;37:2768—801.
- 355 9. Gopal S, Miller KB, Jaffe IZ. Molecular mechanisms for vascular complications of targeted cancer therapies.
 356 Clin Sci (Lond). 2016 Oct 1;130(20):1763–79.
- 357 10. Ginckels P, Holvoet P. Oxidative Stress and Inflammation in Cardiovascular Diseases and Cancer: Role of
 358 Non-coding RNAs. Yale J Biol Med. 2022 Mar;95(1):129–52.
- Janssen-Heijnen ML, Szerencsi K, van de Schans SA, Maas HA, Widdershoven JW, Coebergh JW. Cancer
 patients with cardiovascular disease have survival rates comparable to cancer patients within the age-cohort
 of 8 years older without cardiovascular morbidity. Crit Rev Oncol Hematol 2010;76:196–207.
- 362 9. Leiva O, AbdelHameid D, Connors J, et al. Common Pathophysiology in Cancer, Atrial Fibrillation,
 363 Atherosclerosis, and Thrombosis. J Am Coll Cardiol CardioOnc. 2021 Dec, 3 (5) 619–634.
- 364 10. Luigi Giusto Spagnoli, Elena Bonanno, Giuseppe Sangiorgi, Alessandro Mauriello
- 365 Role of Inflammation in Atherosclerosis. Journal of Nuclear Medicine Nov 2007, 48 (11) 1800-1815.
- 366 11. Libby P, Kobold S. Inflammation: a common contributor to cancer, aging, and cardiovascular diseases-367 expanding the concept of cardio-oncology. Cardiovasc Res. 2019 Apr 15;115(5):824-829
- 368 12. Armenian SH, Xu L, Ky B, Sun C, Farol LT, Pal SK, et al. Cardiovascular Disease Among Survivors of Adult 369 Onset Cancer: A Community-Based Retrospective Cohort Study. J Clin Oncol. 2016;34(10):1122-30.
- 370 13. Patnaik JL, Byers T, DiGuiseppi C, Dabelea D, Denberg TD. Cardiovascular disease competes with breast
 371 cancer as the leading cause of death for older females diagnosed with breast cancer: a retrospective cohort
 372 study. Breast Cancer Res. 2011 Jun 20;13(3):R64.
- 14. Thygesen K, Alpert JS, Jaffe AS, Chaitman BR, Bax JJ, Morrow DA, et al. Fourth Universal Definition of Myocardial Infarction (2018). Circulation. 2018;138(20):e618-e51.
- 375 15. Sacco RL, Kasner SE, Broderick JP, Caplan LR, Connors JJ, Culebras A, et al. An updated definition of stroke
- for the 21st century: a statement for healthcare professionals from the American Heart Association/American
 Stroke Association. Stroke. 2013;44(7):2064-89.
- 378 16. Leiva, O, Xia, Y, Siddiqui, E. et al. Outcomes of Patients With Myeloproliferative Neoplasms Admitted With
- 379 Myocardial Infarction: Insights From National Inpatient Sample. J Am Coll Cardiol CardioOnc. 2023 Aug, 5 (4)380 457–468.
- 17. Hibler, E, Tanaka, Y, Akhter, N. et al. Risk of Incident Heart Failure Among Young Adult Cancer Survivors. J
 Am Coll Cardiol CardioOnc. 2023 Aug, 5 (4) 539–541.
- 383 18. Gangaraju, R, Chen, Y, Hageman, L. et al. Prediction of Coronary Heart Disease Events in Blood or Marrow
- 384 Transplantation Recipients. J Am Coll Cardiol CardioOnc. 2023 Aug, 5 (4) 504–517.

- 385 19. Bima, P, Lopez-Ayala, P, Koechlin, L. et al. Chest Pain in Cancer Patients: Prevalence of Myocardial 386 Infarction and Performance of High-Sensitivity Cardiac Troponins. J Am Coll Cardiol CardioOnc. 2023 Oct, 5 (5) 387 591-609.
- 388 20. Tabata, N., Sueta, D., Yamamoto, E., et al. Outcome of current and history of cancer on the risk of 389 cardiovascular events following percutaneous coronary intervention: A Kumamoto University malignancy and 390 Atherosclerosis (KUMA) study. Eur Heart J. 2017 Dec, 4(4), 290–300.
- 391 21. Cohen JB, Brown NJ, Brown SA, Dent S, van Dorst DCH, Herrmann SM, et al. Cancer Therapy-Related
- 392 Hypertension: A Scientific Statement From the American Heart Association. Hypertension. 2023;80(3):e46-e57.
- 393 22. Cohen JB, Geara AS, Hogan JJ, Townsend RR. Hypertension in Cancer Patients and Survivors: Epidemiology, 394 Diagnosis, and Management. JACC CardioOncol. 2019;1(2):238-51.
- 395 23. Perelshtein Brezinov, et al. Prognostic value of ejection fraction in patients admitted with acute coronary 396 syndrome: A real world study. Medicine. 2017; 96(9):p e6226.
- 397 24. Furtado et al. Long-term mortality after acute coronary syndromes among patients with normal, mildly 398 reduced, or reduced ejection fraction. ESC Heart Fail. 2023 Feb;10(1):442-452.
- 399 25. Joseph JJ, Deedwania P, Acharya T, Aguilar D, Bhatt DL, Chyun DA, et al. Comprehensive Management of 400 Cardiovascular Risk Factors for Adults With Type 2 Diabetes: A Scientific Statement From the American Heart 401 Association. Circulation. 2022;145(9):e722-e59.
- 402 26. Wright, et al. Risk Factor Control and Cardiovascular Event Risk in People With Type 2 Diabetes in Primary 403 and Secondary Prevention Settings. Circulation. 2020 Nov 17;142(20):1925-1936.
- 404 27. Sayed A, Munir M, Addison D, Abushouk AI, Dent SF, Neilan TG, et al. The underutilization of preventive 405 cardiovascular measures in patients with cancer: an analysis of the Behavioural Risk Factor Surveillance 406 System, 2011-22. Eur J Prev Cardiol. 2023;30(13):1325-32.
- 407 28. Belzile-Dugas E, Eisenberg MJ. Radiation-Induced Cardiovascular Disease: Review of an Underrecognized 408 Pathology. J Am Heart Assoc. 2021;10(18):e021686.
- 409 29. Cuomo JR, Javaheri SP, Sharma GK, Kapoor D, Berman AE, Weintraub NL. How to prevent and manage 410 radiation-induced coronary artery disease. Heart. 2018;104(20):1647-53.
- 411 30. Banfill K, Giuliani M, Aznar M, Franks K, McWilliam A, Schmitt M, et al. Cardiac Toxicity of Thoracic 412 Radiotherapy: Existing Evidence and Future Directions. J Thorac Oncol. 2021;16(2):216-27.
- 413 31. Tapia-Vieyra JV, Delgado-Coello B, Mas-Oliva J. Atherosclerosis and Cancer; A Resemblance with Far-414 reaching Implications. Arch Med Res. 2017;48(1):12-26.
- 415 32. Narayan V, Thompson EW, Demissei B, Ho JE, Januzzi JL, Jr., Ky B. Mechanistic Biomarkers Informative of 416 Both Cancer and Cardiovascular Disease: JACC State-of-the-Art Review. J Am Coll Cardiol. 2020;75(21):2726-37.
- 417 33. John A, Gunes C, Bolenz C, Vidal YSS, Bauer AT, Schneider SW, Gorzelanny C. Bladder cancer-derived
- 418
- interleukin-1 converts the vascular endothelium into a pro-inflammatory and pro-coagulatory surface. BMC 419 Cancer. 2020;20(1):1178.
- 420 34. Tran J, Norton R, Conrad N, Rahimian F, Canoy D, Nazarzadeh M, Rahimi K. Patterns and temporal trends of
- 421 comorbidity among adult patients with incident cardiovascular disease in the UK between 2000 and 2014: A
- 422 population-based cohort study. PLoS Med 2018;15:e1002513